arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Tango Therapeutics, Inc.

TNGX
$20.86 ▼ -2.30 (-9.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tango Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.1B
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC -5.8% ↗
FCF / Share $-0.26 ↗
Trailing P/E —
Price / Book 3.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-45.51M
↓ -14.1% —
Operating Margin Operating profit as % of sales
26.2%
↑ +109.2% 1th
FCF / Share Free cash flow per share
$-0.26
↑ +22.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↓
23
Cash Quality ↑
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters